Cancer

SARMs RAD 140 (Testolone) and IBUTAMOREN MK-677 SARMS Stack: Crazy Bulk Lunch Rad 140 Effective Sarms for Bulking and Muscle Growth in 2025

Read about Crazybulk SARMs Rad 140 (Testolone) Rad 140 Benefits and Side Effects, What Is Rad 140, Rad 140 Cycle,…

2 months ago

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming…

2 months ago

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

         EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One®…

2 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and…

2 months ago

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses…

2 months ago

ESMO releases first-ever guidance for safe use of AI Language Models in cancer care

The ELCAP guidance sets standards for responsible AI use in oncology, protecting patients and supporting clinicians LUGANO, Switzerland and BERLIN,…

2 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…

2 months ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

2 months ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…

2 months ago

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

 Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…

2 months ago